Lenalidomide (Леналидомид) is commonly used in situations involving certain distressing symptoms related to specific blood disorders. The primary therapeutic application is for managing conditions such as Multiple Myeloma (MM), certain Non-Hodgkin Lymphomas (including Follicular and Marginal Zone), and specific Myelodysplastic Syndromes (MDS) associated with chronic, severe anemia.

The medication plays a role in managing the proliferation of malignant cells, which is a condition presenting with systemic or localized discomfort in MM. For qualifying patients with MDS, it is applied in addressing the symptom cluster of transfusion-dependent anemia.

“The treatment supports the patient’s comprehensive long-term health management by aiming to support a durable response and maintaining functional stability.”

---

Quick Fact: Relief for Chronic Anemia and Malignancy Symptoms

Lenalidomide assists with easing the overall symptom burden by achieving disease control in blood cancers. For MDS patients, it provides support that helps patients work toward transfusion independence, which helps improve day-to-day comfort and may assist with easing the reliance on frequent supportive care.

Eligibility Map: Official Regulatory Information

The eligibility for using Lenalidomide is strictly defined by government regulatory authorities (e.g., FDA, EMA) based on absolute contraindications, patient age, reproductive status, and specific organ function.

Classification	Population/Condition	Restriction Status
Absolute Contraindication	Pregnancy	Must not be used (Risk of severe birth defects).
	Severe Hypersensitivity	Must not be used (History of severe allergic reactions like angioedema).
Age Restriction	Pediatric Patients	Use not established (Safety/efficacy not demonstrated in children).
	Adult Patients	Approved (All indications are specified for adults).
Conditional Use	Females of Reproductive Potential	Restricted (Must comply with the REMS/Pregnancy Prevention Program and use two forms of contraception).
	Patients with Renal Impairment	Conditional (Use is permitted, but the starting dose must be adjusted based on creatinine clearance).
Disease Limitation	Chronic Lymphocytic Leukemia (CLL)	Not recommended (Not indicated for use outside of controlled clinical trials).

Treatment is intended for eligible adults diagnosed with Multiple Myeloma, Myelodysplastic Syndromes (del 5q), or certain Non-Hodgkin Lymphomas. Additionally, treatment must not be initiated if the patient’s baseline Absolute Neutrophil Count (ANC) or platelet count falls below specific regulatory thresholds.

Interactions with other medicines and products

The official interaction profile for Lenalidomide is defined by specific pharmacodynamic risks and selective pharmacokinetic changes.

---

Documented Pharmacodynamic and PK Effects

Co-administration with certain medicinal product categories carries a documented pharmacodynamic risk. Both Erythropoietin Stimulating Agents and Estrogen-Containing Therapies are associated with an increased risk of venous thromboembolic events (VTE) when combined with Lenalidomide.

A pharmacokinetic interaction is documented with Digoxin: co-administration results in an increase in Digoxin plasma levels (both maximum concentration and total exposure). Regulatory documents recommend periodic monitoring of Digoxin plasma levels when this combination is used.

Lenalidomide is not classified as a clinically significant inhibitor or inducer of major cytochrome P450 (CYP) enzymes. This includes CYP1A2, CYP2C9, and CYP3A4, indicating a limited potential for altering the metabolism of most co-administered medicines.

---

Administration and Disposition

The drug may be taken with or without food. While food reduces the drug's maximum plasma concentration (Cmax), the total extent of absorption (AUC) remains unchanged. No mandatory timing separation rules are specified for co-administered medicinal products.

A population-specific constraint exists for individuals with renal impairment: Lenalidomide is primarily excreted unchanged by the kidney, and reduced renal function leads to decreased clearance and significantly increased systemic exposure.

️ How Леналидомид Works

Cereblon Modulation and Targeted Protein Degradation

Lenalidomide operates primarily as a modulator of the Cereblon (CRBN) E3 Ligase complex, a key component of the cell’s protein degradation machinery. By binding to CRBN, the drug alters the complex’s substrate specificity, a process known as neo-substrate recruitment. This action tags specific, growth-associated transcription factors, notably Ikaros (IKZF1) and Aiolos (IKZF3), with ubiquitin chains. Subsequent destruction of these factors by the cellular proteasome leads directly to apoptosis (cell death) in the target cell population.

Enhancement of Cytotoxic Immunity

The mechanism includes profound effects on immune pathways. Lenalidomide enhances the function and proliferation of cytotoxic immune cells, specifically T-cells and Natural Killer (NK) cells, shifting the immune balance toward cytotoxic activity. Concurrently, the drug dampens the production of growth-associated inflammatory mediators, such as TNF-alpha and IL-6, creating an environment with reduced support for cell survival and propagation.

Restriction of Angiogenesis

The physiological effects extend to vascularization. Lenalidomide restrains the formation of new blood vessels, a process known as angiogenesis, by inhibiting the synthesis of key signaling factors like Vascular Endothelial Growth Factor (VEGF). This action constrains the delivery of nutrients and oxygen, thereby limiting the conditions necessary for cellular proliferation.

How to Use Lenalidomide

Lenalidomide is administered via the oral route as a hard capsule, which is the only approved administration method. The capsule must be swallowed whole with water and must not be opened, broken, or chewed. For consistency, the medicine should be taken at about the same time each day, and intake is permitted with or without food.

---

Dosing Patterns and Schedules

The medicine's usage is structured around 28-day cycles, with dosing frequency being once daily across all approved indications. The starting dose, typically 10 mg, 20 mg, or 25 mg, depends heavily on the specific condition being managed.

Treatment follows one of two main patterns:

• Intermittent Cyclic Pattern: The dose is taken on Days 1–21 of the 28-day cycle, followed by a seven-day break. This schedule is common for induction or combination therapy.
• Continuous Pattern: The dose is taken Days 1–28 of the repeated 28-day cycles, typically for maintenance therapy.

Treatment is generally continued until disease progression or unacceptable toxicity. For Follicular and Marginal Zone Lymphoma, use is typically limited to a maximum of 12 cycles in combination regimens.

---

Procedural Administration Rules

Procedural Constraint	Official Rule
Renal Impairment	Dosage must be adjusted based on the patient's Creatinine Clearance (CLcr).
Missed Dose Rule	If the usual time is missed by less than 12 hours, the dose should be taken. If more than 12 hours have passed, the missed dose is skipped.

This structured approach to administration, frequency, and dosing adjustment is defined by established guidelines to standardize the use of the medicine.

Research evidence / Overview of studies for Lenalidomide (Леналидомид)

---

Evidence for use in Multiple Myeloma (MM)

The clinical evaluation of Lenalidomide for Multiple Myeloma was studied for use in a series of large Phase III Randomized Controlled Trials (RCTs). These studies were used in research exploring outcomes for newly diagnosed patients, as well as those whose disease had returned or progressed after initial treatment (relapsed/refractory MM). The main outcomes research examined included Overall Survival (OS) and Progression-Free Survival (PFS)—these are time-to-event measures that were used to track the duration of specific disease outcomes. Studies monitored measured changes in the disease across the observed populations, reporting rates of Objective Response (ORR) and the duration of those measured outcomes. Full characterization of the long-term outcomes and durability of response beyond the initial trial period is an ongoing focus.

---

Evidence for use in Myelodysplastic Syndromes (MDS)

Research examining Lenalidomide for Myelodysplastic Syndromes (MDS) focused on a very specific patient group: adults with Low- or Intermediate-1-Risk MDS who have transfusion-dependent anemia and possess a specific deletion 5q cytogenetic abnormality. The evidence base for this indication includes dedicated Phase II and Phase III studies. The primary outcome was studied for the achievement and length of time of Red Blood Cell Transfusion Independence (TI). Reported data indicated patterns in outcomes observed primarily in the del(5q) population. Because this research was conducted on a highly defined patient subset, the results apply only to the populations studied.

---

Evidence for use in Follicular and Marginal Zone Lymphoma

For certain types of non-Hodgkin lymphoma, specifically Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL), Lenalidomide was evaluated in combination with rituximab in Phase III Randomized Controlled Trials (RCTs). The patient populations included adults with previously treated or relapsed/refractory disease. The research examined Progression-Free Survival (PFS) and monitored the percentage of patients whose disease was tracked with a defined reduction (Objective Response Rate). Evidence generally focuses on the drug's use in combination therapy, which may make it challenging to isolate the specific influence of Lenalidomide in the regimen.

---

The Research Landscape: Areas of Uncertainty

A key uncertainty noted across several indications is the need for more complete and consistent long-term data, particularly to fully characterize the long-term effects associated with years of treatment. Comparative evidence may be lacking in the setting of rapidly evolving treatment standards. Research highlights that while findings describe group patterns, research does not determine whether an individual will respond similarly, and research is ongoing to fill these identified gaps.

Key Studies & References

1. Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality (NCT00065156)

Common questions about Леналидомид (FAQ)

---

Q: Can I drink alcohol while taking Lenalidomide?

Official product information indicates there is no known direct interaction between Lenalidomide and alcohol. However, regulatory documents state that alcohol may intensify some common side effects of the medicine, such as dizziness, fatigue, and diarrhea. Additionally, the combination may increase the risk of liver problems.

Q: Does Lenalidomide affect the ability to drive?

Because Lenalidomide is associated with side effects such as dizziness, fatigue, and blurred vision, official safety guidance suggests avoiding driving or operating machinery. If a patient experiences these symptoms, they should wait until they are certain the medicine does not impair their motor skills.

Q: How soon after starting can one expect the first results?

The time required to achieve a measurable response can vary widely depending on the individual patient and the condition being treated. While research measures outcomes over months, clinical trials often reassessed disease status every two months to track progress and identify a response.

Q: Is Lenalidomide treatment associated with hair loss?

Hair loss (alopecia) has been reported as a side effect in regulatory documents. This indicates that while it is possible, official information suggests the frequency of its occurrence is not widely established or is less common than other reported effects.

Q: Can Lenalidomide be used in elderly patients?

Yes, Lenalidomide has been used in clinical trials in patients up to 95 years of age, and the data did not show a difference in efficacy based on age alone. However, since older patients are more likely to have reduced kidney function, official guidance states that the starting dose may need adjustment to prevent increased side effects.

Q: Why is Lenalidomide sometimes prescribed in combination with other drugs, such as Dexamethasone?

Lenalidomide is often used in combination with Dexamethasone as a standard initial therapy for certain conditions like Multiple Myeloma. This is based on clinical trial evidence showing that the combination regimen is associated with improved response rates and survival outcomes compared to using the agents alone.

Q: Does Lenalidomide affect patient weight?

Yes, the official safety profile for Lenalidomide includes reported changes in weight. Decreased appetite and weight loss are reported as common side effects. Weight gain has also been reported in clinical studies, although less frequently.

Q: What is known about using Lenalidomide during breastfeeding?

Due to potential risk to the infant, official regulatory information states that Lenalidomide must not be used by females who are breastfeeding. It is currently unknown if the medicine passes into breast milk and whether it could cause harm to the infant.

Q: Is it true that taking Lenalidomide can cause peripheral neuropathy?

Yes, symptoms consistent with peripheral neuropathy, such as numbness, tingling, or burning sensations in the fingers or toes, have been reported in the medicine's safety profile. This is classified as a common side effect.

Q: Does Lenalidomide affect fertility?

Regulatory warnings focus on the risk of birth defects. The medicine can pass into semen, which is why men must use condoms and not donate sperm during treatment and for a period afterward. The official documents do not detail the long-term biological effect on fertility itself.

Q: Does Lenalidomide affect blood pressure?

Yes, regulatory documents note that Lenalidomide has been reported to cause changes in blood pressure. This includes episodes of both high blood pressure and low blood pressure, particularly a sudden drop upon standing (orthostatic hypotension).

Q: Does Lenalidomide contain lactose or other allergens?

Yes, official product information confirms that Lenalidomide capsules contain the excipient lactose (anhydrous). Official product information notes that patients with lactose intolerance should be aware of this excipient.

Q: How often is blood testing required during Lenalidomide treatment?

Regulatory guidelines require frequent monitoring of blood counts. Blood work is required weekly for the initial eight weeks (two cycles) of therapy. Following this intensive period, testing is generally required at least monthly, depending on the specific condition and treatment protocol.

Q: Are there restrictions on taking other medicines or supplements with Lenalidomide?

Regulatory safety documents mandate that patients inform their doctor about all medicines they take. This requirement includes not only prescription drugs, but also vitamins, herbal products, and other supplements, as interactions may occur that are not specifically documented in the official interaction profile.

Q: How long does a typical course of Lenalidomide treatment last?

The duration of treatment is determined by the disease's response and patient tolerability. Treatment is generally continued for as long as the disease is controlled and side effects remain acceptable, which is described as until disease progression or unacceptable toxicity.

Q: Why is Lenalidomide taken in cycles, not continuously?

Lenalidomide is administered in repeated cycles, typically consisting of a period of treatment followed by a break (e.g., 21 days on and 7 days off). This cyclic schedule is used to maximize tolerability and give the body time to recover from side effects like low blood counts, allowing the treatment to continue for the longest possible duration.

Q: Are there any diet or lifestyle restrictions while taking Lenalidomide?

Yes, official guidelines impose several safety and lifestyle restrictions. Patients must not donate blood or sperm during treatment and for a specified time after stopping. Additionally, official guidance advises taking precautions to avoid sun exposure due to increased skin sensitivity.

Q: Can the side effects of Lenalidomide appear a long time after the end of treatment?

Yes, a key long-term safety concern documented in research is the risk of developing a new cancer, known as a Second Primary Malignancy (SPM). This risk, involving new blood disorders or solid tumors, has been observed in patients during long-term follow-up after receiving Lenalidomide therapy.

Q: Why must patients enroll in a special program to receive Lenalidomide?

Patients must be enrolled in the controlled distribution program, such as the REMS program, because of the high risk of severe birth defects (Embryo-Fetal Toxicity) or fetal death. This required program ensures that the serious risks and the specific safe-use conditions are followed by all parties involved.

Lenalidomide capsules must be stored in strict accordance with regulatory requirements to maintain product stability and prevent unintentional exposure.

Storage and Handling

Requirement	Condition
Temperature	Store at controlled room temperature (mathbf20 C to mathbf25 C)
Container	Keep in the original container and ensure the cap remains tightly closed
Protection	Keep the medicine out of the reach of children
Capsule Integrity	Do not open, break, crush, or chew the capsules

Disposal Instructions

Unused or outdated lenalidomide capsules must not be kept for later use. For proper disposal, the medication must be returned to the healthcare provider, the dispensing pharmacy, or a designated drug take-back program. It is essential not to flush the capsules down the toilet or pour them into a drain, reflecting the official requirement for controlled, specialized disposal.